u 74006f has been researched along with Extravascular Hemolysis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bacznskyj, O; Buffenbarger, SL; Buxser, SE; Decker, D; Epps, DE; Guido, DM; Knechtel, TJ; Lutzke, BS; Mathews, WR; McCall, JM | 1 |
| Dzik, WH; Sadrzadeh, SM; Sharifi, S | 1 |
2 other study(ies) available for u 74006f and Extravascular Hemolysis
| Article | Year |
|---|---|
Tirilazad mesylate protects stored erythrocytes against osmotic fragility.
Topics: Antioxidants; Blood Preservation; Dinoprost; Erythrocyte Membrane; Hemolysis; Humans; In Vitro Techniques; Osmotic Fragility; Pregnatrienes; Time Factors; Vitamin E | 1994 |
Human plasma and tirilazad mesylate protect stored human erythrocytes against the oxidative damage of gamma-irradiation.
Topics: Antioxidants; Blood Preservation; Cell Survival; Erythrocytes; Evaluation Studies as Topic; Free Radical Scavengers; Gamma Rays; Graft vs Host Disease; Hemolysis; Humans; Lipid Peroxidation; Osmotic Fragility; Oxidative Stress; Plasma; Pregnatrienes; Radiation Tolerance; Radiation-Protective Agents; Thiobarbituric Acid Reactive Substances | 2000 |